公开(公告)号：US06953808B2

公开(公告)日：2005-10-11

申请号：US10757059

申请日：2004-01-14

Applicant: Nancy M. Gray

Inventor： Nancy M. Gray

IPC: C07D401/12 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P1/04

CPC classification number: A61K31/4439 ,  A61K31/44

Abstract: Methods and compositions are disclosed utilizing optically pure (−) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Pantoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯的（ - ）泮托拉唑用于治疗人类溃疡的方法和组合物，同时显着降低与泮托拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（ - ）异构体也可用于治疗胃食管反流。 （ - ）泮托拉唑是释放H +的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症如Zollinger-Ellison综合征。

公开(公告)号：US5955478A

公开(公告)日：1999-09-21

申请号：US754657

申请日：1996-11-21

Applicant: Nancy M. Gray ,  James W. Young

Inventor： Nancy M. Gray ,  James W. Young

IPC: C07D211/62 ,  A61K31/445 ,  A61K31/4468 ,  A61P1/00 ,  A61P1/08 ,  A61P1/10 ,  A61P1/14

CPC classification number: A61K31/445 ,  A61K31/4468

Abstract: Methods are disclosed utilizing the optically pure (+) isomer of cisapride. The optically pure (+) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.

Abstract translation: 公开利用西沙必利的光学纯（+）异构体的方法。 西沙必利的光学纯（+）异构体可用于治疗消化不良和其他可能与（+）西沙必利作为促动力剂的活性相关的其它病症，如胃轻瘫，便秘，手术后肠梗阻和 肠假性梗阻，没有与西沙必利的外消旋混合物相关的副作用的伴随的责任。 西沙必利的（+）异构体也表现出比外消旋西沙必利更长的作用时间，并且可用于治疗中枢神经系统疾病。

公开(公告)号：US5627183A

公开(公告)日：1997-05-06

申请号：US622617

申请日：1996-03-26

Applicant: Nancy M. Gray

Inventor： Nancy M. Gray

IPC: C07D241/04 ,  A61K31/495 ,  A61P11/00 ,  A61P37/08

CPC classification number: A61K31/495

Abstract: Methods are disclosed utilizing optically pure (+) cetirizine for the treatment of urticaria in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine.

Abstract translation: 公开了利用光学纯（+）西替利嗪治疗人类荨麻疹的方法，同时避免与西替利嗪的外消旋混合物相关的副作用的伴随的责任。

公开(公告)号：US5508279A

公开(公告)日：1996-04-16

申请号：US206764

申请日：1994-03-07

Applicant: Nancy M. Gray

Inventor： Nancy M. Gray

IPC: C07D405/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/496 ,  A61K31/505 ,  A61K31/517 ,  A61P9/10 ,  A61P13/08 ,  A61P35/00 ,  C07D237/10 ,  A61K31/495

CPC classification number: A61K31/505

Abstract: Methods are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin.

Abstract translation: 利用多沙唑嗪的光学纯（+）异构体公开了方法。 该化合物是治疗良性前列腺增生的有效药物，同时避免与多沙唑嗪的外消旋混合物相关的降压作用的伴随责任。

公开(公告)号：US5629328A

公开(公告)日：1997-05-13

申请号：US135769

申请日：1993-10-12

Applicant: Nancy M. Gray ,  James W. Young

Inventor： Nancy M. Gray ,  James W. Young

IPC: C07D211/62 ,  A61K31/445 ,  A61K31/4468 ,  A61P1/00 ,  A61P1/08 ,  A61P1/10 ,  A61P1/14

CPC classification number: A61K31/445 ,  A61K31/4468

Abstract: Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is useful in treating emesis while substantially reducing adverse effects associated with racemic cisapride.

Abstract translation: 公开利用西沙必利的光学纯（+）异构体的方法。 该化合物可用于治疗呕吐，同时显着降低与西西沙必利素有关的不良反应。

公开(公告)号：US5618828A

公开(公告)日：1997-04-08

申请号：US135776

申请日：1993-10-12

Applicant: Nancy M. Gray ,  James W. Young

Inventor： Nancy M. Gray ,  James W. Young

IPC: C07D211/62 ,  A61K31/445 ,  A61K31/4468 ,  A61P1/00 ,  A61P1/08 ,  A61P1/10 ,  A61P1/14

CPC classification number: A61K31/445 ,  A61K31/4468

Abstract: Methods are disclosed utilizing the optically pure (-) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while substantially reducing adverse effects associated with racemic cisapride.

Abstract translation: 公开利用西沙必利的光学纯（ - ）异构体的方法。 该化合物是用于治疗胃食管反流疾病的有效药物，同时显着减少与西沙必利的外消旋混合物相关的副作用的伴随的责任。 该化合物也可用于治疗或预防呕吐，同时显着降低与西西沙必利素有关的不良反应。

公开(公告)号：US5510352A

公开(公告)日：1996-04-23

申请号：US207802

申请日：1994-03-07

Applicant: Nancy M. Gray

Inventor： Nancy M. Gray

IPC: C07D405/12 ,  A61K31/505 ,  A61P9/10 ,  A61K31/495

CPC classification number: A61K31/505

Abstract: Methods are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of doxazosin.

Abstract translation: 利用多沙唑嗪的光学纯（+）异构体公开了方法。 该化合物是治疗高血压的有效药物，同时避免与多沙唑嗪的外消旋混合物相关的副作用的伴随责任。

公开(公告)号：US5089506A

公开(公告)日：1992-02-18

申请号：US516364

申请日：1990-04-30

Applicant: Nancy M. Gray ,  Brian K. Cheng

Inventor： Nancy M. Gray ,  Brian K. Cheng

IPC: A61K31/395 ,  A61K31/40 ,  A61K31/415 ,  A61K31/42 ,  A61K31/425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/535 ,  A61K31/5375 ,  A61K31/545 ,  A61K31/55 ,  A61P9/10 ,  A61P25/08 ,  A61P25/18 ,  A61P25/28 ,  C07D295/02 ,  C07D295/033 ,  C07D295/04

CPC classification number: C07D295/033 ,  C07C2103/68 ,  C07C2103/72

Abstract: Certain ethanobicyclic amine compounds are described for treatment of CNS disorders such as psychotic disorders, convulsions, dystonia and cerebral ischemia. Compounds of particular interest are of the formula ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, phenalkyl, phenyl, alkoxy, phenoxy, phenalkoxy, alkoxyalkyl, halo, haloalkyl and hydroxyalkyl; wherein R.sup.3 and R.sup.4 may be taken together to form oxo;wherein each of R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, fluoroalkyl, cycloalkylalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein G within the nitrogen-containing cyclohetero moiety is selected from ##STR2## wherein R.sup.11 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenalkyl, alkoxyalkyl and hydroxyalkyl wherein each of R.sup.12 and R.sup.13 is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, fluoroalkyl and fluoro; wherein m is one or two; wherein p is a number selected from zero through four, inclusive; wherein each of q and r is a number independently selected from one through three, inclusive, with the proviso that sum of q and r is a number from three through six, inclusive; with the further proviso that the nitrogen-containing cyclohetero moiety must be attached at one position selected from R.sup.3, R.sup.4, ring-position two, and ring-position three; or the pharmaceutically-acceptable salts thereof.

公开(公告)号：US5955477A

公开(公告)日：1999-09-21

申请号：US752984

申请日：1996-11-21

Applicant: Nancy M. Gray ,  James W. Young

Inventor： Nancy M. Gray ,  James W. Young

IPC: C07D211/62 ,  A61K31/445 ,  A61K31/4468 ,  A61P1/00 ,  A61P1/08 ,  A61P1/10 ,  A61P1/14

CPC classification number: A61K31/445 ,  A61K31/4468

Abstract: The optically pure (-) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (-) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (-) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.

Abstract translation: 西沙必利的光学纯（ - ）异构体可用于治疗消化不良和其他可能与（ - ）西沙必利作为促动力剂如胃轻瘫，便秘，手术后肠梗阻和肠道活动有关的其他病症 假性梗阻，没有与西沙必利的外消旋混合物有关的副作用的伴随的责任。 西沙必利的（ - ）异构体也表现出比外消旋西沙必利更长的作用时间，并且可用于治疗中枢神经系统疾病。

公开(公告)号：US5888535A

公开(公告)日：1999-03-30

申请号：US772944

申请日：1996-12-23

Applicant: Nancy M. Gray

Inventor： Nancy M. Gray

IPC: C07D401/12 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P1/04 ,  A61K9/127

CPC classification number: A61K31/4439 ,  A61K31/44

Abstract: Methods and compositions are disclosed utilizing optically pure (-) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (-) isomer is also useful for the treatment of gastroesophageal reflux. (-) Pantoprazole is an inhibitor of H.sup.+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯的（ - ）泮托拉唑用于治疗人类溃疡的方法和组合物，同时显着降低与泮托拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（ - ）异构体也可用于治疗胃食管反流。 （ - ）泮托拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。